Contact

All Stories

  1. Semaglutide in MASH with F2-F3 fibrosis: a holistic perspective on the ESSENCE phase 3 trial

    Article • Metabolism and Target Organ Damage, April 2026, OAE Publishing

    Dr Silvia Sookoian

  2. Sex-specific cardiometabolic phenotypes in MASLD: 3PM-centric stratification and trajectory mapping for proactive risk assessment

    Article • The EPMA Journal, April 2026, Springer Science + Business Media

    Dr Silvia Sookoian

  3. Therapeutic targets for metabolic dysfunction-associated steatohepatitis: a personalized approach to disease management

    Article • Nature Reviews Gastroenterology & Hepatology, March 2026, Springer Science + Business Media

    Dr Silvia Sookoian

  4. Panomics in metabolic dysfunction-associated steatotic liver disease: unravelling the drivers of disease heterogeneity

    Article • Clinical and Molecular Hepatology, January 2026, The Korean Association for the Study of the Liver (KAMJE)

    Dr Silvia Sookoian

  5. Proteomic signature of MASLD heterogeneity reveals sex-driven endotypes and predicts all-cause mortality

    Article • December 2025, openRxiv

    Dr Silvia Sookoian

  6. Focus on Semaglutide 2.4 mg/week for the Treatment of Metabolic Dysfunction‐Associated Steatohepatitis

    Article • Liver International, October 2025, Wiley

    Dr Silvia Sookoian

  7. Organ damage proteomic signature identifies patients with MASLD at-risk of systemic complications

    Article • Hepatology, May 2025, Wolters Kluwer Health

    Dr Silvia Sookoian

  8. Identifying molecular pathways of olfactory dysfunction in Parkinson’s disease through a systems biology framework

    Article • Neuroscience, May 2025, Elsevier

    Dr Silvia Sookoian

  9. Global Burden of Major Chronic Liver Diseases in 2021

    Article • Liver International, March 2025, Wiley

    Dr Silvia Sookoian

  10. MASLD as a non-communicable disease

    Article • Nature Reviews Gastroenterology & Hepatology, February 2025, Springer Science + Business Media

    Dr Silvia Sookoian

  11. Global, regional, and national burden of primary liver cancer attributable to metabolic risks: an analysis of the Global Burden of Disease Study 1990-2021

    Article • The American Journal of Gastroenterology, January 2025, Wolters Kluwer Health

    Dr Silvia Sookoian

  12. The Proteomics of MASLD Progression: Insights From Functional Analysis to Drive the Development of New Therapeutic Solutions

    Article • Alimentary Pharmacology & Therapeutics, January 2025, Wiley

    Dr Silvia Sookoian

  13. Corrigendum to “Cross talk between the liver microbiome and epigenome in patients with metabolic dysfunction-associated steatotic liver disease”

    Article • EBioMedicine, January 2025, Elsevier

    Dr Silvia Sookoian

  14. Metabolic dysfunction-associated steatotic liver disease exhibits sex-specific microbial heterogeneity within intestinal compartments

    Article • Clinical and Molecular Hepatology, January 2025, The Korean Association for the Study of the Liver (KAMJE)

    Dr Silvia Sookoian

  15. Organ damage proteomic signature identifies patients with MASLD at-risk of systemic complications

    Article • November 2024, Cold Spring Harbor Laboratory Press

    Dr Silvia Sookoian

  16. Global Epidemiological Impact of PNPLA3 I148M on Liver Disease

    Article • Liver International, October 2024, Wiley

    Dr Silvia Sookoian

  17. Genetics of MASLD: The State of Art Update.

    Article • Clinical Gastroenterology and Hepatology, July 2024, Elsevier

    Dr Silvia Sookoian

  18. The gene expression signature of metabolic dysfunction- associated steatotic liver disease from a multiomics perspective

    Article • Clinical and Molecular Hepatology, April 2024, The Korean Association for the Study of the Liver (KAMJE)

    Dr Silvia Sookoian

  19. Cross talk between the liver microbiome and epigenome in patients with metabolic dysfunction-associated steatotic liver disease

    Article • EBioMedicine, March 2024, Elsevier

    Dr Silvia Sookoian

  20. Drug repurposing in MASLD and MASH-cirrhosis: Targets and treatment approaches based on pathways analysis

    Article • January 2024, Elsevier

    Dr Silvia Sookoian

  21. From NAFLD to MASLD: Updated Naming and Diagnosis Criteria for Fatty Liver Disease

    Article • Journal of Lipid Research, December 2023, Elsevier

    Dr Silvia Sookoian

  22. Non‐alcoholic fatty liver disease mediates the effect of obesity on arterial hypertension

    Article • Liver International, June 2023, Wiley

    Dr Silvia Sookoian

  23. SARS-CoV-2 targets the liver and manipulates glucose metabolism

    Article • Trends in Molecular Medicine, June 2023, Elsevier

    Dr Silvia Sookoian

  24. Editorial: NAFLD , chronic kidney disease, and pleiotropy—Why is PNPLA3 omnipresent?

    Article • Alimentary Pharmacology & Therapeutics, April 2023, Wiley

    Dr Silvia Sookoian

  25. Advances in our understanding of the molecular heterogeneity of fatty liver disease: towards informed treatment decision making

    Article • Expert Review of Gastroenterology & Hepatology, March 2023, Taylor & Francis

    Dr Silvia Sookoian

  26. Genetics in non-alcoholic fatty liver disease: The role of risk alleles through the lens of immune response

    Article • Clinical and Molecular Hepatology, February 2023, The Korean Association for the Study of the Liver (KAMJE)

    Dr Silvia Sookoian

  27. COVID ‐19 and NAFLD : biological insights from multi‐omics data

    Article • Liver International, January 2023, Wiley

    Dr Silvia Sookoian

  28. Personalized medicine in nonalcoholic fatty liver disease

    Article • Clinical and Molecular Hepatology, October 2022, The Korean Association for the Study of the Liver (KAMJE)

    Dr Silvia Sookoian

  29. Repurposing drugs to target nonalcoholic steatohepatitis: Auranofin, a gold-organic molecule complex for the treatment of a specifc complex trait

    Article • Clinical and Molecular Hepatology, October 2022, The Korean Association for the Study of the Liver (KAMJE)

    Dr Silvia Sookoian

  30. Geographical similarity and differences in the burden and genetic predisposition of NAFLD

    Article • Hepatology, September 2022, Wiley

    Dr Silvia Sookoian

  31. Alcohol consumption and metabolic syndrome: Clinical and epidemiological impact on liver disease

    Article • Journal of Hepatology, September 2022, Elsevier

    Dr Silvia Sookoian

  32. Single cell gene expression profiling of nasal ciliated cells reveals distinctive biological processes related to epigenetic mechanisms in patients with severe COVID-19

    Article • Computers in Biology and Medicine, July 2022, Elsevier

    Dr Silvia Sookoian, Luis Diambra

  33. The serum uric acid/creatinine ratio is associated with nonalcoholic fatty liver disease in the general population

    Article • Journal of Physiology and Biochemistry, May 2022, Springer Science + Business Media

    Dr Silvia Sookoian

  34. PNPLA3 rs738409 and risk of fibrosis in NAFLD: Exploring mediation pathways through intermediate histological features

    Article • Hepatology, April 2022, Wiley

    Dr Silvia Sookoian

  35. MicroRNAs as messengers of liver diseases: has the message finally been decrypted?

    Article • Clinical Science, March 2022, Portland Press Ltd.

    Dr Silvia Sookoian

  36. The influence of host genetics on liver microbiome composition in patients with NAFLD

    Article • EBioMedicine, February 2022, Elsevier

    Dr Silvia Sookoian

  37. Computational Pipeline for Next-Generation Sequencing (NGS) Studies in Genetics of NASH

    Article • January 2022, Springer Science + Business Media

    Dr Silvia Sookoian

  38. Single cell gene expression profiling of nasal ciliated cells reveals distinctive biological processes related to epigenetic mechanisms in patients with severe COVID-19

    Article • December 2021, Cold Spring Harbor Laboratory Press

    Dr Silvia Sookoian

  39. Genome‐wide association study of liver‐related enzymes suggests putative pleiotropic effects on diverse traits and diseases

    Article • Hepatology, September 2021, Wiley

    Dr Silvia Sookoian

  40. PNPLA3 and COVID‐19 outcomes: Thinking outside the box might explain the biology behind pleiotropic effects of rs738409 on the immune system

    Article • Liver International, September 2021, Wiley

    Dr Silvia Sookoian

  41. Editorial: bariatric surgery to reduce the risk of liver cancer

    Article • Alimentary Pharmacology & Therapeutics, April 2021, Wiley

    Dr Silvia Sookoian

  42. The lipidome in nonalcoholic fatty liver disease: actionable targets

    Article • Journal of Lipid Research, January 2021, Elsevier

    Dr Silvia Sookoian

  43. NAFLD and cardiometabolic risk factors: The liver fibrosis trajectory through the lens of biological interactions

    Article • Hepatology, December 2020, Wiley

    Dr Silvia Sookoian

  44. Liver mitochondrial DNA damage and genetic variability of Cytochrome b ‐ a key component of the respirasome ‐ drive the severity of fatty liver disease

    Article • Journal of Internal Medicine, July 2020, Wiley

    Dr Silvia Sookoian

  45. Epigenetics factors in nonalcoholic fatty liver disease

    Article • Expert Review of Gastroenterology & Hepatology, June 2020, Taylor & Francis

    Dr Silvia Sookoian

  46. ADH1B∗2 Is Associated With Reduced Severity of Nonalcoholic Fatty Liver Disease in Adults, Independent of Alcohol Consumption

    Article • Gastroenterology, May 2020, Elsevier

    Dr Silvia Sookoian

  47. SARS‐CoV‐2 virus and liver expression of host receptors: Putative mechanisms of liver involvement in COVID‐19

    Article • Liver International, April 2020, Wiley

    Dr Silvia Sookoian

  48. COVID-19 and ACE2 in the Liver and Gastrointestinal Tract: Putative Biological Explanations of Sexual Dimorphism

    Article • Gastroenterology, April 2020, Elsevier

    Dr Silvia Sookoian

  49. Genetic pathways in nonalcoholic fatty liver disease: Insights from systems biology

    Article • Hepatology, March 2020, Wiley

    Dr Silvia Sookoian

  50. Liver tissue microbiota linked to nonalcoholic fatty liver disease

    Article • Gut, January 2020, BMJ

    Dr Silvia Sookoian, Dr. Carlos Jose Pirola

  51. Review article: shared disease mechanisms between non-alcoholic fatty liver disease and metabolic syndrome - translating knowledge from systems biology to the bedside

    Article • Alimentary Pharmacology & Therapeutics, February 2019, Wiley

    Dr Silvia Sookoian

  52. Splice variant rs72613567 prevents worst histologic outcomes in patients with nonalcoholic fatty liver disease

    Article • Journal of Lipid Research, October 2018, American Society for Biochemistry & Molecular Biology (ASBMB)

    Dr Silvia Sookoian

  53. Editorial: surviving your genes-the role of PNPLA3 variation in end-stage liver disease

    Article • Alimentary Pharmacology & Therapeutics, September 2018, Wiley

    Dr Silvia Sookoian

  54. A Rare Nonsense Mutation in the Glucokinase Regulator Gene Is Associated With a Rapidly Progressive Clinical Form of Nonalcoholic Steatohepatitis

    Article • Hepatology Communications, September 2018, Wiley

    Dr Silvia Sookoian

  55. Metastasis-associated lung adenocarcinoma transcript 1 as a common molecular driver in the pathogenesis of nonalcoholic steatohepatitis and chronic immune-mediated liver damage

    Article • Hepatology Communications, April 2018, Wiley

    Dr Silvia Sookoian

  56. Lack of evidence supporting a role of TMC4-rs641738 missense variant—MBOAT7- intergenic downstream variant—in the Susceptibility to Nonalcoholic Fatty Liver Disease

    Article • Scientific Reports, March 2018, Springer Science + Business Media

    Dr Silvia Sookoian

  57. The nonalcoholic steatohepatitis metabotype: Imbalance of circulating amino acids and transamination reactions reflect impaired mitochondrial function

    Article • Hepatology, January 2018, Wiley

    Dr Silvia Sookoian

  58. Systematic review with meta-analysis: the significance of histological disease severity in lean patients with nonalcoholic fatty liver disease

    Article • Alimentary Pharmacology & Therapeutics, October 2017, Wiley

    Dr Silvia Sookoian

  59. Letter: Mendelian randomisation to investigate moderate alcohol consumption in nonalcoholic fatty liver disease; modest effects need large numbers-authors' reply

    Article • Alimentary Pharmacology & Therapeutics, July 2017, Wiley

    Dr Silvia Sookoian

  60. Systematic review with meta-analysis: risk factors for non-alcoholic fatty liver disease suggest a shared altered metabolic and cardiovascular profile between lean and obese patients

    Article • Alimentary Pharmacology & Therapeutics, May 2017, Wiley

    Dr Silvia Sookoian

  61. How Safe Is Moderate Alcohol Consumption in Overweight and Obese Individuals?

    Article • Gastroenterology, June 2016, Elsevier

    Dr Silvia Sookoian

  62. Serum aminotransferases in nonalcoholic fatty liver disease are a signature of liver metabolic perturbations at the amino acid and Krebs cycle level,

    Article • American Journal of Clinical Nutrition, January 2016, American Society for Nutrition

    Dr Silvia Sookoian, Dr Silvia Sookoian